Didanosine
drugOn this page
Also known as (-)-didanosineBMY-40900DdiDidanosinaDidanosine system suitability mixtureDidanosinumDideoxyinosine (ddi)NSC-612049VidexVidex ec2',3'-dideoxyinosinedideoxyinosineSID17389541SID26719672SID29215491SID26757698SID49718183SID267545105'-O-2',3'-dideoxyinosine
Summary
Didanosine (CHEMBL1460) is an approved small-molecule HIV-1 reverse transcriptase inhibitor (ATC J05AF02); indicated across 7 conditions including hiv infectious disease and viral infectious disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J05AF02
- Indications: 7 conditions
- Clinical trials: 129
- Chemistry: 236.23 Da · C10H12N4O3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1460 |
| Name | Didanosine |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 135398739 |
| ChEBI | CHEBI:490877 |
| ATC | J05AF02 |
| Molecular formula | C10H12N4O3 |
| Molecular weight | 236.23 |
| InChIKey | BXZVVICBKDXVGW-NKWVEPMBSA-N |
SMILES: C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O
IUPAC name: 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
ChEBI definition: A purine 2’,3’-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2’ and the 3’ positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.
Pharmacological roles (ChEBI): HIV-1 reverse transcriptase inhibitor, antiviral drug, EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor, geroprotector.
Other ChEBI roles (chemical / environmental): antimetabolite.
Also known as: (-)-didanosine, BMY-40900, Ddi, Didanosina, Didanosine, Didanosine system suitability mixture, Didanosinum, Dideoxyinosine (ddi), NSC-612049, Videx, Videx ec, didanosine
Patent coverage: 23,015 distinct patent families (89,412 SureChEMBL compound mentions), from 4 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prelamin-A/C, Albumin, Aldehyde dehydrogenase 1A1, Mitogen-activated protein kinase 1.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| HIV infectious disease | 4 | MONDO:0005109 | EFO:0000764 |
| viral infectious disease | 4 | MONDO:0005108 | EFO:0000763 |
| AIDS | 3 | MONDO:0012268 | EFO:0000765 |
| AIDS related complex | 3 | MONDO:0005639 | EFO:0007137 |
| tuberculosis | 3 | MONDO:0018076 | MONDO:0018076 |
| lymphoma | 2 | MONDO:0005062 | EFO:0000574 |
| AIDS dementia complex | 2 | MONDO:0020689 | EFO:0002608 |
Clinical trials
Total trials: 129.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 48 |
| PHASE1 | 27 |
| Not specified | 24 |
| PHASE3 | 21 |
| PHASE4 | 8 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00002376 | PHASE4 | COMPLETED | The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients |
| NCT00002386 | PHASE4 | COMPLETED | Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia |
| NCT00005000 | PHASE4 | UNKNOWN | Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs |
| NCT00005018 | PHASE4 | COMPLETED | Safety and Effectiveness of a Combination Anti-HIV Drug Treatment |
| NCT00084136 | PHASE4 | COMPLETED | Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings |
| NCT00192660 | PHASE4 | COMPLETED | HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) |
| NCT00256828 | PHASE4 | COMPLETED | Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV |
| NCT00342355 | PHASE4 | COMPLETED | Antiretroviral Therapy for Advanced HIV Disease in South Africa |
| NCT00000637 | PHASE3 | COMPLETED | A Randomized Comparative Trial of Zidovudine (AZT) Versus 2’,3’-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children |
| NCT00001022 | PHASE3 | COMPLETED | A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected Patients |
| NCT00001267 | PHASE3 | COMPLETED | A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2’,3’-Dideoxyinosine |
| NCT00002109 | PHASE3 | COMPLETED | Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy |
| NCT00002123 | PHASE3 | COMPLETED | A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3 |
| NCT00002224 | PHASE3 | COMPLETED | Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI) |
| NCT00002230 | PHASE3 | COMPLETED | A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients |
| NCT00002429 | PHASE3 | COMPLETED | Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen |
| NCT00006154 | PHASE3 | COMPLETED | A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection |
| NCT00006208 | PHASE3 | UNKNOWN | A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs |
| NCT00006397 | PHASE3 | UNKNOWN | Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs |
| NCT00008489 | PHASE3 | UNKNOWN | Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults |
| NCT00013520 | PHASE3 | COMPLETED | Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection |
| NCT00074581 | PHASE3 | COMPLETED | Preventing Sexual Transmission of HIV With Anti-HIV Drugs |
| NCT00102960 | PHASE3 | COMPLETED | Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth |
| NCT00135382 | PHASE3 | COMPLETED | Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen |
| NCT00158470 | PHASE3 | COMPLETED | Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR) |
| NCT00196612 | PHASE3 | COMPLETED | Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART |
| NCT00332306 | PHASE3 | UNKNOWN | Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment |
| NCT00338390 | PHASE3 | COMPLETED | Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC |
| NCT00427297 | PHASE3 | TERMINATED | Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya |
| NCT00000625 | PHASE2 | COMPLETED | A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3 |
| NCT00000657 | PHASE2 | COMPLETED | Comparison of 2’,3’-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex |
| NCT00000671 | PHASE2 | COMPLETED | A Phase II Efficacy Study Comparing 2’,3’-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment |
| NCT00000672 | PHASE2 | COMPLETED | An Efficacy Study of 2’,3’-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex |
| NCT00000770 | PHASE2 | COMPLETED | A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine |
| NCT00000781 | PHASE2 | COMPLETED | A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3) |
| NCT00000803 | PHASE2 | COMPLETED | A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy |
| NCT00000823 | PHASE2 | COMPLETED | A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection |
| NCT00000831 | PHASE2 | COMPLETED | Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy |
| NCT00000838 | PHASE2 | COMPLETED | Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine |
| NCT00000851 | PHASE2 | COMPLETED | Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).